Form 13F-HR REGENERON PHARMACEUTICAL For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US stock futures edge up as oil falls heading into earnings barrage
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
Leerink: 'We continue to recommend REGN shares'
August 4, 2025 10:20 AM EDTLeerink Partners analyst Andrew Berens reiterated an Outperform rating and $645.00 price target on Regeneron Pharma (NASDAQ: REGN).
The analyst comments "Bottom Line: We continue to recommend REGN shares based upon improving growth prospects and attractive valuation. We project 5-yr (2025-2030) CAGR rev +7% and EPS +10%. Mgmt emphasized Lynozyfics... More



